Skip to main content

Partial-edentulism

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
Half-guided implant placementPhase 4
Innovation Pharmaceuticals
1 program
1
Half-guided implant placementPhase 41 trial
Active Trials
NCT04854239Completed40Est. Jan 2019
Geistlich Pharma
Geistlich PharmaSwitzerland - Root
1 program
Split-thickness groupPHASE_41 trial
Active Trials
NCT05538715Unknown44Est. Sep 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Geistlich PharmaSplit-thickness group
Innovation PharmaceuticalsHalf-guided implant placement

Clinical Trials (2)

Total enrollment: 84 patients across 2 trials

NCT05538715Geistlich PharmaSplit-thickness group

Reconstruction of Localized Alveolar Ridge Defects

Start: Nov 2019Est. completion: Sep 202444 patients
Phase 4Unknown
NCT04854239Innovation PharmaceuticalsHalf-guided implant placement

Accuracy of Half-guided Implant Placement

Start: Jan 2017Est. completion: Jan 201940 patients
Phase 4Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.